Authors Zivin and Simmons explain how the remarkable drug tPA came to be used for stroke survivors, the drug's infancy and childhood within the pharmaceutical giant Genentech, and its eventual marginalization due to a convergence of unfortunate political, fiscal, and medical circumstances.